121 -5 (79) 2025 - Ruziyev Z.M. - THE RELATIONSHIP BETWEEN LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AND PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 (PCSK9) IN FAMILIAL HYPERCHOLESTEROLEMIA: PHYSIOLOGICAL ROLE, PATHOGENESIS OF VASCULAR DEMENTIA, AND POTEN

THE RELATIONSHIP BETWEEN LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AND PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 (PCSK9) IN FAMILIAL HYPERCHOLESTEROLEMIA: PHYSIOLOGICAL ROLE, PATHOGENESIS OF VASCULAR DEMENTIA, AND POTENTIAL AS A BIOMARKER

Ruziyev Z.M. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The group IV phospholipase A2 (PLA2) family includes six intracellular enzymes (GIVA, -B, -C, -D, -E, and -F), known as cytosolic phospholipases A2 (cPLA2). These enzymes possess a serine-asparagine catalytic dyad, and all except cPLA2 have a C2 domain. Differences in their catalytic activity and subcellular localization suggest unique regulation and functions. cPLA2 catalyzes the hydrolysis of phospholipids to produce arachidonic acid and lysophospholipids, which serve as precursors for numerous biologically active lipids. The regulation of cPLA2 is complex and involves both transcriptional and post-translational mechanisms, particularly increases in intracellular calcium levels and phosphorylation. It is a widely distributed and highly conserved enzyme involved in the production of lipid mediators in human and rodent cells. The bioactive lipids generated by cPLA2 regulate both normal physiological processes and the pathogenesis of diseases in various organs. However, a recently identified deficiency of cPLA2 in humans is associated with more severe clinical impairments than those observed in cPLA2-deficient mice, indicating the need for further investigation of this enzyme

Keywords: Phospholipase A2 family, Lp-PLA2, hypercholesterolemia, dyslipidemia

First page

595

Last page

599

For citation:Ruziyev Z.M. - THE RELATIONSHIP BETWEEN LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AND PROPROTEIN CONVERTASE SUBTILISIN-KEXIN TYPE 9 (PCSK9) IN FAMILIAL HYPERCHOLESTEROLEMIA: PHYSIOLOGICAL ROLE, PATHOGENESIS OF VASCULAR DEMENTIA, AND POTENTIAL AS A BIOMARKER//New Day in Medicine 5(79)2025 595-599 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

1. К.С. Бенимецкая, В.С. Шрамко, Е.М. Стахнёва, К.В. Макаренкова, Л.В. Щербакова, Ю.И. Рагино, М.И. Воевода. Связь Липопротеин-Ассоциированной Фосфолипазы А2 (Лп-Фла2) И Пропротеиновой Конвертазы Субтилизин-Кексинового Типа 9 (Pcsk9) При Семейной Гиперхолестеринемии//Научно-практический журнал Атеросклероз. 2019. Т. 15, 1
2. Christina C. Leslie. Cytosolic phospholipase A 2: physiological function and role in disease// Journal of Lipid Research Volume 56, 2015
3. Giovanni Zuliani, Judit Marsillach, Alessandro Trentini, Valentina Rosta and Carlo Cervellati. Lipoprotein-Associated Phospholipase A2 Activity as Potential Biomarker of Vascular Dementia// Antioxidants 2023, 12, 597. https://doi.org/10.3390/ antiox12030597
4. Fubao Huang, Kai Wang, Jianhua Shen. Lipoprotein‐associated phospholipase A2: The story continues// wileyonlinelibrary.com/journal/med. Med Res Rev. 2020;40:79-134
5. Naghavi M., Wang H., Lozano R. et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015. Vol. 385. P. 117–171.
6. Bonnefont-Rousselot D. Lp-PLA2, a biomarker of vascular inflammation and vulnerability ofatherosclerosis plaques // Ann. Pharm. Fr. 2016. Vol. 74. P. 190–197.
7. Thompson A., Gao P., Orfei L., Watson S., di Angelantonio E., Kaptoge S., Ballantyne C., Cannon C.P., Criqui M., Cushman M., Hofman A., Packard C., Thompson S.G., Collins R., Danesh J. Lipoproteinassociated phospholipase A2 and risk of coronary
8. Disease, stroke, and mortality: collaborative analysis of 32 prospective studies // Lancet. 2010. Vol. 375. P. 1536–1544.
9. Jellinger P.S., Handelsman Y., Rosenblit P.D., Bloomgarden Z.T., Fonseca V.A., Garber A.J., Grunberger G., Guerin C.K., Bell D.S.H., Mechanick J.I., Pessah-Pollack R., Wyne K., Smith D., Brinton E.A., Fazio S., Davidson M., Zangeneh F., Bush M.A.
10. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease-executive summary // Endocr. Pract. 2017. Vol. 23, N 4. P. 479–497.

    file

    download